SBRT controlled bone lesions but rarely delayed systemic therapy in bladder cancer
Two-year local control reached 88%, but median progression-free survival was 5.8 months and systemic treatment changed after 4.4 months.
Tag
bladder
Bladder dose escalation reduced invasive recurrence without increasing toxicity
Two-year invasive recurrence fell from 27.5% to 5.5% with dose escalation, without higher grade 2 or greater toxicity.
USP15-FIS1 signaling sensitized bladder cancer to radiotherapy through mitochondrial dysfunction
USP15 stabilized FIS1, suppressed oxidative phosphorylation, and increased radiosensitivity; metformin restored radiation response in USP15-low bladder cancer models.